Trial · NCT04372615
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
NCT04372615, Phase 2, Recruiting, University of Utah
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis. Trials, record NCT04372615. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04372615
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
- NCT number
- NCT04372615
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 116 participants, estimated
- Lead sponsor
- University of Utah
- Conditions
- Autoimmune Encephalitis, Encephalitis
- Interventions
- Inebilizumab, Placebo
- First posted
- 2020-05-04
- Last updated
- 2025-07-01
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change of modified Rankin score at 16 weeks | 16 weeks | Change in modified Rankin score (mRS) (0 to 6; 0=normal and 6=death) at 16 weeks determined by rank analyses, integrating need for rescue therapy and time to achievement of the mRS. |
| Primary | Inebilizumab safety measures by the number of treatment-emergent adverse events and serious adverse events | 96 weeks | Inebilizumab safety, as measured by the number of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs) |
| Secondary | Time to mRS ≤ 2, corrected for baseline value. | 96 weeks | Time to mRS ≤ 2, corrected for baseline value. |
| Secondary | Clinical Assessment Scale in Autoimmune Encephalitis (CASE) Score (continuous logistic regression), corrected from baseline value to week 24 (weeks 6 and 16). | 16 weeks | Clinical Assessment Scale in Autoimmune Encephalitis (CASE) Score (ranges of 0 to 27 with 0 being normal and 27 being worse)(continuous logistic regression), corrected from baseline value to week 24 (weeks 6 and 16). |
| Secondary | mRS at week 6 as measured by proportional odds logistic regression/shift analysis. | 6 weeks | mRS at week 6 as measured by proportional odds logistic regression/shift analysis. |
| Secondary | Proportion of participants who meet the protocol-defined criteria for needing rescue therapy at week 6. | 6 weeks | Proportion of participants who meet the protocol-defined criteria for needing rescue therapy at week 6. |
| Secondary | Cognitive outcome at week 24 as measured by mean scaled score on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) + components of Delis-Kaplan Executive Function System (D-KEFS). | 24 weeks | Cognitive outcome at week 24 as measured by mean scaled score on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) + components of Delis-Kaplan Executive Function System (D-KEFS). |
| Secondary | Survival as measured by a Kaplan-Meier analysis. | 96 weeks | Survival as measured by a Kaplan-Meier analysis. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers39
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04372615
GET https://conductscience.org/api/trials/v1/NCT04372615/papers?page=2